All the components of the vaccine candidate were well tolerated by the participants with no serious adverse events reported. HIV-CORE 006 took place at four vaccine trial sites in Kenya, Uganda and Zambia. These are promising results, and an important step in developing an HIV vaccine that can protect people against HIV infection in all parts of the world. These activities focused on preparing the CRCs to participate in future HIV vaccine research and clinical trials. Through this trial, the consortium members have contributed to strengthening the capacity of the partnering clinical research centers to conduct robust HIV vaccine research and clinical trials.
